Published on the Packaging World Web site
| November 30, 1997
In an October 27 public hearing on FDA's proposed regulation on mandatory pediatric labeling for drugs and biologics, the American Academy of Pediatrics (AAP) recommended the formation of a pediatric drug labeling advisory panel to determine, among other things, which drugs really need to be studied.
Use of an advisory panel that represents the interests of both the medical community and drug manufacturers may alleviate or minimize the concerns of both sides said the AAP spokesperson. At the same hearing an executive of pharmaceutical giant Merck Research Labs said it is critical to prioritize the need for labeling of drugs already on the market. He said FDA AAP and other pediatric groups should identify compounds most in need of pediatric study and labeling.
© Copyright 2014 Summit Media Group, Inc. This copy is for your personal, noncommercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers click HERE
or use the "Reprints" tool that appears next to any article. Visit www.summitreprints.com
for samples and additional information. Order a reprint or license this article now.